OncLive TV

Kevin Kalinsky, MD, MS, FASCO, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer.

Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.

Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference.

Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities.

Matthew D. Galsky, MD, discusses the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer.

Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

Vincent Picozzi, MD, discusses how data from the phase 3 PANOVA-3 trial are foundational for the evaluation of Optune Pax with other immunotherapies.

Alexander T. Pearson, MD, PhD, discusses how AI can be used for oncologic drug discovery and development.

Sunandana Chandra, MD, discusses the current systemic treatment landscape for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.

Megan Kruse, MD, emphasizes the importance of observing Triple-Negative Breast Cancer Day through continued disease education and treatment development.

Tycel Phillips, MD, discusses ongoing clinical trials in mantle cell lymphoma and how their data may influence the field.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss how they go about determining which patients are suitable candidates for clinical trials.

Alexander T. Pearson, MD, PhD, discusses how he uses AI in his current daily practice.

Ranee Mehra, MD, highlights how the ongoing OrigAMI-5 study may address an unmet need for patients with treatment-naive, recurrent or metastatic HNSCC.

Ranee Mehra, MD, discusses the design of the OrigAMI-5 trial of pembrolizumab plus amivantamab and carboplatin for recurrent or metastatic HNSCC.

Sarah Sammons, MD, discusses efficacy data from a phase 2 study of pumitamig in patients with locally advanced or metastatic triple-negative breast cancer.

Toni K. Choueiri, MD, discusses data from the phase 3 LITESPARK-022 trial in ccRCC after nephrectomy.

Andrea Necchi, MD, discusses final data from the SunRISe-2 study of the gemcitabine intravesical system plus cetrelimab in MIBC.

Ravi A. Madan, MD, discusses data from a phase 2 trial of enzalutamide monotherapy in patients with biochemically recurrent prostate cancer.

Jose Mauricio Mota, MD, PhD, discusses results from the Daro-PET study, which evaluated whether short-course darolutamide increases PSMA expression in prostate cancer.

Ranee Mehra, MD, discusses the toxicities associated with subcutaneous amivantamab in recurrent or metastatic HNSCC.

Alan H. Bryce, MD, discusses the implications of the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Ranee Mehra, MD, discusses the efficacy of subcutaneous amivantamab plus pembrolizumab in patients with first-line recurrent or metastatic HNSCC.

Enrique Gallardo, MD, discusses final OS data from the phase 3 PEACE-3 trial of radium-223 with/without enzalutamide in mCRPC.

Stacy Loeb, MD, discusses findings from a study evaluating microplastics in prostate cancer tissue.

Vernon Sondak, MD, discusses the importance of accurately distinguishing advanced cutaneous squamous cell carcinoma from basal cell carcinoma.

Balazs Halmos, MD, MS, highlights the significance of the accelerated approval of zongertinib in HER2 TKD–mutated non–small cell lung cancer.

Richard Kim, MD, discusses how data from the phase 3 POD1UM-303 trial inform the use of retifanlimab plus chemotherapy in frontline metastatic SCAC.

Igor Makhlin, MD, discusses the evolving role of FES-PET/CT as a tool to aid in the diagnosis and management of estrogen receptor–positive breast cancer.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the importance of clinical trials in gynecologic oncology.